ArticleArthritis research & therapy2025
Serum CXCL6 as a biomarker for diagnosing and predicting progression of interstitial lung disease in ANCA-associated vasculitis.
Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate serum CXCL6 as a biomarker at diagnosis and predict progression of interstitial lung disease (ILD) in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
methodsBaseline serum CXCL6 levels were measured in 292 AAV patients and 82 healthy controls. Correlations with clinical parameters and disease activity were examined. To assess its role in ILD progression, the association between baseline CXCL6 levels and ILD progression during follow up was evaluated using univariable and multivariable analyses.
resultsSerum CXCL6 levels were significantly elevated in AAV patients compared to healthy controls, and were markedly higher in those with ILD than without ILD. The frequency of ILD in AAV patients with high serum CXCL6 levels was significantly higher compared with low levels group (54% vs. 36%, P = 0.002). Serum CXCL6 levels at baseline correlated positively with disease activity of AAV, and acute-phase reactants (ESR and CRP). Among AAV-ILD patients, high serum CXCL6 levels were associated with a significantly higher frequency of ILD progression during follow-up compared to low levels (53.8% vs. 30.0%, P = 0.023). Critically, high baseline CXCL6 level was independently associated with ILD progression in multivariate regression analysis.
conclusionsThis exploratory study suggests that elevated serum CXCL6 levels are associated with greater frequency and disease progression of ILD in AAV patients. Serum CXCL6 may represent a promising serological biomarker for identifying AAV-ILD and monitoring its progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.